American Marconi Wireless News - CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

NYSE - LSE

RIO	0.88%	78.32	$
SCS	0.12%	16.14	$
CMSC	-0.52%	23.17	$
NGG	-0.37%	76.11	$
GSK	0.66%	48.61	$
BCE	-0.04%	22.84	$
BTI	-1.05%	56.45	$
CMSD	-0.13%	23.25	$
AZN	0.82%	91.36	$
BP	1.86%	33.94	$
RYCEF	1.79%	15.68	$
BCC	-3.92%	74.77	$
JRI	-0.37%	13.38	$
VOD	0.31%	12.84	$
RELX	0.2%	40.73	$
RBGPF	0%	80.22	$

CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

BOULEVARD 03.09.2025

SOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 3, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced that David Cory, CEO, will present a company update at the H.C. Wainwright 27^th Annual Global Investment Conference on September 8, 2025 at 10:00 AM ET.

Text size:

CASI will also host one-on-one meetings with investors at the conference.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a publicly-traded, biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.

CID-103 is a fully human IgG1, potentially best-in-class, clinical stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated an encouraging pre-clinical efficacy and clinical safety profile compared to other anti-CD38 monoclonal antibodies, and for which CASI owns exclusive global rights. CASI is actively recruiting and dosing patients in a Phase 1 / 2 study in immune thrombocytopenic purpura (ITP). In parallel, CASI recently received FDA IND clearance to conduct a Phase 1/2 study in renal allograft antibody-mediated rejection (AMR) with plans for first patient in Q1 2026.

More information on CASI is available at www.casipharmaceuticals.com.

COMPANY CONTACT:

Ingrid Choong, PhD
650-619-6115
[email protected]

SOURCE: CASI Pharmaceuticals, Inc.

View the original press release on ACCESS Newswire

M.Fischer--AMWN

American Marconi Wireless News - CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

Featured

Gang members given hundreds-years-long sentences in El Salvador

Gang members given hundred-years-long sentences in El Salvador

Gunmen kill 9, wound 10 in South Africa bar attack

Taiwan police rule out 'terrorism' in metro stabbing